Colorectal cancer remains one of the most common types of
cancer and a leading cause of
cancer death worldwide. In this study, we aimed to investigate effects of
DuP-697, an irreversible selective inhibitor of COX- 2 on
colorectal cancer cells alone and in combination with a promising new multi-targeted
kinase inhibitor
E7080. The HT29
colorectal cancer cell line was used. Real time cell analysis (xCELLigence system) was conducted to determine effects on colorectal cell proliferation, angiogenesis was assessed with a chorioallantoic membrane model and apoptosis was determined with
annexin V staining. We found that
DuP-697 alone exerted antiproliferative, antiangiogenic and apoptotic effects on HT29
colorectal cancer cells. For the antiproliferative effect the half maximum inhibition concentration (IC50) was 4.28?10-8 mol/L. Antiangiogenic scores were 1.2, 0.8 and 0.5 for 100, 10 and 1 nmol/L
DuP-697 concentrations, respectively. We detected apoptosis in 52% of HT29
colorectal cancer cells after administration of 100 nmol/L
DuP-697. Also in combination with the thyrosine
kinase inhibitor
E7080 strong antiproliferative, antiangiogenic and apoptotic effects on HT29
colorectal cancer cells were observed. This study indicates that
DuP-697 may be a promising agent in the treatment of
colorectal cancer. Additionally the increased effects observed in the combination with thyrosine
kinase inhibitor give the possibility to use lower doses of
DuP-697 and
E7080 which can avoid and/or minimize side effects.